logo2


Pharamasaga is a drug discovery and development company. We aim to develop novel anti-diabetic small-molecule drugs that can treat and reverse diabetes. Pdia4 was identified as a therapeutic target that promotes beta-cell failure and diabetes. By combining molecular docking, chemical synthesis and bioassays, Pdia4 inhibitors were developed as first-in-class drugs that can preserve beta cell mass and function and treat and reverse diabetes.

One of Pdia4 inhibitor, PS1, was approved by US FDA for its IND in 2022.

觀看詳細

tittle

Blog Image   

EMBO Molecular Medicine

Diabetes has been shown to be caused by the loss and function of Beta cells (β-cells) in pancreatic islets, which are regions of the pancreas that contain hormone-producing cells. Yang Wen-chin (楊文欽) and his team at Academia Sinica's Agricultural Biotechnology Research Center (ABRC) have discovered through experiments on mice that the protein-coding gene, Pdia4 (Protein Disulfide Isomerase Family A Member 4), is responsible for the destruction of β-cells and that inhibiting this gene can prevent and even reverse the loss of such cells.

Read More
Blog Image   

Taiwanese scientists discover potential cure for diabetes

Nutrient overload increases oxidative stress (e.g., ROS) in beta cells. Consequently, ROS causes beta-cell dysfunction and death and, in turn, type 2 diabetes (T2D). Of note, Pdia4 was first identified as a central player that controls ROS production in beta cells. Conversely, a Pdia4 inhibitor, PS-001, can preserve beta cell mass and function and, subsequently, reverse diabetes. This preservation involves novel mechanism - inhibition of Pdia4-mediated ROS production pathways.

Read More
Blog Image   

Youtube

Taiwanese scientists have discovered a key mechanism that causes diabetes and developed a new drug treatment that could "fully reverse" the disease, according to reports.

Read More